Article

Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical response

2025-01-14

Abstract excerpt

There is an urgent need of precision medicine for ovarian cancer patients to identify patients who respond to chemotherapy and PARP inhibitors, a therapy targeting homologous recombination deficiency (HRD). Here we established a panel of 37 long-term patient-derived tumor organoids (PDTO) models of various histological subtypes from 224 patients and demonstrated that they mimic the histological and molecular chara...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0a801efd-e291-5c22-b927-f358c7387921
DOI: 10.1101/2025.01.10.631512

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical responseDOI 10.1101/2025.01.10.631512Read

Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and intrapatient drug responsesSemantic proximity Read

Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug ResponsesSemantic proximity Read

The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testingSemantic proximity Read

Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer OrganoidsSemantic proximity Read

Exploiting a living biobank to delineate mechanisms underlying disease-specific chromosome instabilitySemantic proximity Read

Genomic analysis of patient-derived xenograft models reveals intra-tumor heterogeneity in endometrial cancer and can predict tumor growth inhibition with talazoparibSemantic proximity Read

PARPi Decreased Primary Ovarian Cancer Organoid Growth Through Early Apoptosis and Base Excision Repair PathwaySemantic proximity Read

HRDetect in Ovarian Carcinoma: Stratification and Therapeutic ImplicationsSemantic proximity Read

Longitudinal Prediction of Drug Response in High-Grade Serous Ovarian Cancer Organoid Cultures Aligning with Clinical ResponsesSemantic proximity Read

Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testingSemantic proximity Read

Ovarian Cancer Patient-Derived Organoids Used as a Model for Replicating Genetic Characteristics and Testing Drug Responsiveness: A Preliminary Study.Semantic proximity Read

Decoding the Genomic and Functional Landscape of Emerging Subtypes in Ovarian CancerSemantic proximity Read